Research
Where the manufacturing rules stop
One short section decides how far the drug-manufacturing rulebook reaches. It stacks rulebooks instead of choosing between them, lets a company answer only for the steps it performs, and switches one rulebook off while leaving the statute behind it standing.
Three paragraphs, three different limits
The part that sits in front of the manufacturing rulebook holds three sections. One states what the rules are and what failing them means. One holds the definitions. The middle one is about applicability.
That middle section is short, and it does three unrelated jobs. It decides what happens when two rulebooks both reach the same product. It decides what a company answers for when it performs only part of the work. And it switches the rulebook off for one narrow case.
Each of the three answers a question readers ask in different words, and none of the three is where anyone looks for it.
Two rulebooks can both apply
The first paragraph gathers the drug rules, the rules for biological products for human use, and the rules for a human cell or tissue product regulated as a drug.
It then says how they sit together. Those regulations "shall be considered to supplement, not supersede, each other, unless the regulations explicitly provide otherwise."
So the ordinary answer to "which rulebook applies" is often both. That is worth knowing before reading a claim that a product is made under one particular standard, because naming one rulebook does not displace another.
A conflict rule follows for the case where two do collide. "In the event of a conflict between applicable regulations in this part and in other parts of this chapter, the regulation specifically applicable to the drug product in question shall supersede the more general."
The specific one wins, and only where there is an actual conflict.
You answer for the steps you perform
The second paragraph is one sentence and it explains a great deal about how this market is put together.
It covers a person who "engages in only some operations subject to the regulations" in the named parts, "and not in others". Such a person "need only comply with those regulations applicable to the operations in which the person is engaged".
That is not a way out of the rulebook. It is a statement about which parts of it attach to whom.
It is also why "who made it", "who filled it" and "who labeled it" are three separate questions on a comparison site rather than one. A company doing a single step answers for that step, and says nothing about the others.
Read alongside the accreditation and testing claims sellers publish, the paragraph has a practical edge. A statement about one operation is not a statement about the operation next to it.
The exemption that leaves the statute standing
The third paragraph is the most useful sentence in the part, and it is the one nobody quotes.
It reads: "An investigational drug for use in a phase 1 study, as described in § 312.21(a) of this chapter, is subject to the statutory requirements set forth in 21 U.S.C. 351(a)(2)(B). The production of such drug is exempt from compliance with the regulations in part 211 of this chapter."
Two sentences, pulling in opposite directions on purpose. The long rulebook is switched off. The statutory requirement it implements is expressly left on.
That is the clearest statement anywhere in this rulebook that an exemption from a regulation is not an exemption from the law behind it. The manufacturing-practice duty survives the removal of the manual that describes how to meet it.
A reader who takes only the second sentence has the paragraph exactly backwards.
What a phase 1 study is, read from the section it points at
The paragraph does not define its own trigger. It points at another section, and following the pointer matters here.
That section is titled "Phases of an investigation", and its first paragraph is the one named. Phase 1 "includes the initial introduction of an investigational new drug into humans". Those studies are "designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses".
It also covers studies of drug metabolism, structure-activity relationships and mechanism of action in humans, and studies using an investigational drug as a research tool to explore biological phenomena or disease processes.
Every one of those sits inside an investigational new drug application. This site describes the gate a compound has to pass to get there in a separate article.
That is the scope limit on the whole paragraph, and it is easy to miss. A vial sold with a research-use label is not an investigational drug under an application, and nothing in this exemption reaches it. This site treats that label as its own subject.
And the exemption ends
The paragraph does not stop at the exemption. It carries its own expiry, in two further sentences.
The exemption "does not apply to an investigational drug for use in a phase 1 study" in two situations. The first is where the drug "has been made available for use by or for the sponsor in a phase 2 or phase 3 study". The second is where "the drug has been lawfully marketed".
And the consequence is stated rather than implied. Where either of those has happened, "the drug for use in the phase 1 study must comply with part 211."
So the same material, used for the same purpose, changes rulebook because of something that happened elsewhere in the program.
The same shape, one law over
The pattern in that paragraph repeats in the part of the law this market lives under, and recognizing it saves a lot of confusion.
The compounding exemption is written the same way. It names a short list of sections that do not apply to a qualifying preparation, and everything outside that list stays where it was.
What differs is which sections are on the list. The manufacturing-practice provision is on one compounding route's list and absent from the other, which is why the two routes are not equivalent.
This site covers both routes in their own articles, and the sibling article here follows the manufacturing-practice provision itself.
The general rule is the useful one. An exemption is a list of named things switched off, and the burden is on anyone claiming more than the list says.
Where the vocabulary lives
One structural detail explains why this short part is so rarely read.
The long rulebook contains a definitions section, and that section is a single sentence: the definitions set out in the short part apply in this part.
So the terms the whole manufacturing rulebook runs on are defined one part away, in a place a reader following section numbers will never arrive at.
This site uses one of those definitions where it belongs, in the article on what happens to the powder before it becomes a medicine.
What to hold on to
Two rulebooks reaching one product supplement each other rather than replacing each other, and the specific one wins only an actual conflict.
A company that performs some operations and not others complies with the regulations applicable to what it does, which is why a claim about one step proves nothing about the next.
The one exemption in the section removes a rulebook and expressly preserves the statute behind it, and it ends the moment the program moves on.
And the reach of that exemption is fixed by a cross-reference to a definition of phase 1 written for drugs under an application, not for anything sold with a research label.
Key takeaways
- The applicability section does three unrelated jobs in three short paragraphs.
- Overlapping rulebooks supplement rather than supersede each other, and the specific rule wins only a real conflict.
- A company performing some operations and not others complies with the regulations applicable to what it does.
- The phase 1 exemption removes the regulation and expressly leaves the statutory requirement standing.
- Its trigger is defined by cross-reference to the phases of an investigation under an application, not by a product label.
- The exemption ends once the drug reaches a later phase or is lawfully marketed, and the full rulebook then applies.
- The manufacturing rulebook defines its terms by pointing at the short part in front of it.
Frequently asked questions
If two sets of manufacturing rules apply, which one wins?
Usually neither, because the section says they supplement rather than supersede each other, unless the regulations explicitly provide otherwise. A winner is picked only where there is an actual conflict, and then the rule specifically applicable to the drug product in question supersedes the more general one. So a page that names one standard and implies it displaces another has stated something the applicability section does not say.
Does a company that only performs one step have to follow the whole rulebook?
The section answers this directly. Where a person engages in only some of the operations subject to the named parts and not in others, a limit applies. That person need only comply with the regulations applicable to the operations in which the person is engaged. It is a statement about which rules attach, not an exemption from any of them. It is also the reason a claim about one operation says nothing about the operation next to it.
Is a phase 1 drug exempt from the manufacturing rules?
From the long rulebook, yes, and from the statute behind it, no. The paragraph says an investigational drug for use in a phase 1 study is subject to the statutory manufacturing-practice requirement. It then says that production of such a drug is exempt from compliance with the regulations in that rulebook. Both sentences are in the same paragraph, and reading only the second one reverses it.
Does that exemption apply to a research-use-only vial?
No. The paragraph is written about an investigational drug for use in a phase 1 study as defined in the part on investigational new drug applications. That is a drug under an application filed with the agency. A product sold with a research-use label by a company that has filed nothing is outside the definition, so the paragraph reaches it in no way at all. This site covers what that label does and does not mean separately.
When does the phase 1 exemption end?
The paragraph carries its own expiry. The exemption stops applying once the investigational drug has been made available for use by or for the sponsor in a phase 2 or phase 3 study, or once the drug has been lawfully marketed. Where either has happened, the drug for use in the phase 1 study must comply with the full rulebook. The material and its purpose can be unchanged while the applicable rules change.
Where are the terms in the manufacturing rules defined?
Not in the rulebook that uses them. Its definitions section is one sentence saying that the definitions in the short part before it apply. So the vocabulary the whole manufacturing rulebook runs on lives one part away. A reader working through section numbers can use the terms for a long time without ever reaching the place they are defined.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- Title 21 Code of Federal Regulations section 210.2, Applicability of current good manufacturing practice regulations, read in full including the supplement-not-supersede rule, the conflict rule, the only-some-operations paragraph, and the phase 1 exemption with its statutory carve-out and its expiry — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
- Title 21 Code of Federal Regulations section 312.21, Phases of an investigation, whose paragraph (a) describes phase 1 as the initial introduction of an investigational new drug into humans and whose paragraphs (b) and (c) describe phases 2 and 3 — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
- Title 21 Code of Federal Regulations section 211.3, Definitions, whose entire text provides that the definitions set forth in section 210.3 of that chapter apply in the part — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
- Title 21 United States Code section 353a, Pharmacy compounding, whose opening subsection is written as a list of named sections that shall not apply to a qualifying compounded drug product — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026